ESMO 2023 BioNTech Data

Activity Signals Observed Post Single Infusion BNT221 Monotherapy Phase 1 FIH study (NCT04625205): Clinical Efficacy Borgers J. et al. Presented at ESMO 2023. Abstract #10170. RECIST % Change in Target Lesions 50- 40- 30. 20 10- 0 -10- -20 -30 -40- -50- -60- NAC02 NAC05 NAC06 NAC04 NAC01 NAC07 NAC08 NAC03 NAC09 Patient BOR SD IPD % Change in Sum of Target Lesions BNT221 Infusion 501 40 Pre-infusion Post-infusion 30 20 10. 0 -10- -20 -30 -40- -50 -60 -25 -20 -15 -10 -5 0 5 Study Week 10 15 20 20 Tumor regressions, including prolonged SD in this aPD-1 and a CTLA4 pretreated population NAC: neoantigen cell dose received; PD: progressive disease; SD: stable disease. 25 30 30 35 Patient NAC01 NAC02 ●• NAC03 NAC04 NAC05 • NAC06 NAC07 NAC08 NAC09 BIONTECH

View entire presentation